David J. Borges
Known title: VP, Finance & CAOCIK: 0002005787
Associated companies
Transaction History
| OMER | ▲ Buy | Option Exercise | 10,000 | $156K | 9/23/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 10,000 | $210K | 9/23/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 5,000 | $20K | 9/22/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 5,000 | $15K | 9/22/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 10,000 | $210K | 9/22/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 906 | $17K | 8/24/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 906 | $3K | 8/24/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 5,906 | $23K | 8/21/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 4,094 | $12K | 8/21/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 10,000 | $190K | 8/21/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 5,000 | $20K | 8/13/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 5,000 | $85K | 8/13/2026 | View on chart |
| OMER | ▲ Buy | Option Exercise | 30,000 | $92K | 1/13/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 30,000 | $369K | 1/13/2026 | View on chart |
| OMER | ▼ Sell | Open Market | 30,000 | $382K | 1/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
OMER Shares Fall After European Regulatory Setback
Omeros shares dropped after the Committee for Medicinal Products for Human Use (CHMP) again gave a negative opinion on the drug Narsoplimab. The decision was confirmed by European regulators, marking a second rejection and pushing the stock below its $9.96 support level for the first time in almost three months. The drop comes as the stock shows a moderate RSI of 40.2 and recent volume spikes, indicating increased selling pressure.
OMER Shares Fall After European Regulatory Setback. Omeros shares dropped after the Committee for Medicinal Products for Human Use (CHMP) again gave a negative opinion on the drug Narsoplimab. The decision was confirmed by European regulators, marking a second rejection and pushing the stock below its $9.96 support level for the first time in almost three months. The drop comes as the stock shows a moderate RSI of 40.2 and recent volume spikes, indicating increased selling pressure.